Clozapine: Difference between revisions
Annhuang04 (talk | contribs) |
Annhuang04 (talk | contribs) |
||
| Line 22: | Line 22: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B (no evidence of risk) | ||
*Lactation: | *Lactation: possibly unsafe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
***not defined, consider decreasing dose for significant impairment | |||
**Pediatric | **Pediatric | ||
***not available | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
***not defined, consider decreasing dose for significant impairment | |||
**Pediatric | **Pediatric | ||
***not available | |||
==Indications== | ==Indications== | ||
Revision as of 01:38, 3 September 2015
General
- Type: Atypical antipsychotic
- Dosage Forms:
- 12.5, 25, 50, 100, 200
- 12.5, 25, 50, 100, 150, 200 ODT
- Common Trade Names: Clozaril, FezaClo, Versacloz
Adult Dosing
- schizophrenia, resistant
- 150-300mg PO BID
- start: 12.5mg PO qd-bid, increase by 25-50mg/day to target 300-450mg/day in divided doses by day 14; then may increase by up to 100mg/day q3-7days;
- max 900mg/day
- retitrate from 12.5mg PO qd-bid if treatment interrupted > 2 d
- taper dose over 1-2 weeks to DC
- 150-300mg PO BID
- suicide prevention, schizophrenia-associated
- 150-300mg PO BID
- start, increase, retitrate, and DC as above
- 150-300mg PO BID
Pediatric Dosing
- not available
Special Populations
- Pregnancy Rating: B (no evidence of risk)
- Lactation: possibly unsafe
- Renal Dosing
- Adult
- not defined, consider decreasing dose for significant impairment
- Pediatric
- not available
- Adult
- Hepatic Dosing
- Adult
- not defined, consider decreasing dose for significant impairment
- Pediatric
- not available
- Adult
Indications
- Controls positive and negative symptoms of psychotic disorders
- Used for schizophrenia
- Off label use:
- Bipolar disorder
- Borderline personality disorder
Contraindications
- Allergy to class/drug
Adverse Reactions
- QT prolongation
- Myocarditis
- Agranulocytosis in 1%–2% of patients during initial treatment 3 months
- Highest ~3 months into treatment and then decreases
- Other potential side effects:
- Dyslipidemia
- Diabetes
- Decreased seizure threshold
- "Other adverse cardiovascular and respiratory effects" [1]
- "Increased mortality in elderly patients with dementia-related psychosis"[1]
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
